Cannabis Stocks Rise and Fall on Rescheduling News; Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY) Rollercoaster Morning
Cannabis stocks show volatility as Tilray (NASDAQ: TLRY) reacts to US rescheduling news, marking a major shift in federal cannabis policy.
Cannabis Stocks Rise and Fall on Rescheduling News; Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY) Rollercoaster Morning
(Investorideas.com Newswire) a go-to platform for big investing ideas, including cannabis stocks issues a news and trading alert for Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries.
Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) has already had extreme volatility in early trading, with a day’s range of $7.59 - 9.27. Stocks in the sector ran yesterday and continued gain in early trading, but they are all seeing red now. Tilray is currently trading at 7.69 -0.18(-2.29%).
Tilray today issued a statement applauding President Donald Trump’s actions leading to the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act—a defining inflection point that represents a fundamental shift in U.S. drug policy, unlocking significant opportunities for medical cannabis clinical research, patient access, and industry standardization. The action represents the most consequential federal cannabis policy development in decades, accelerating the emergence of a regulated, science-driven medical cannabis framework in the United States.
Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands, stated:
“Today marks a pivotal moment for the United States. With President Trump’s action to reschedule cannabis, federal policy is finally aligning with science, medicine, and most importantly, patient needs. This is about people: patients fighting cancer, seniors managing chronic pain, veterans navigating PTSD, and children with epilepsy whose families have long sought safe, effective options. For decades, they have turned to medical cannabis. Today, the system begins to catch up with them. Rescheduling has the potential to accelerate clinical research, broaden access, and elevate the quality, consistency, and safety standards that establish medical cannabis as a legitimate pillar of modern healthcare."
“At Tilray, we have built a global platform for precisely this moment. We are among the world’s largest cannabis growers, with more than 7 million square feet of cultivation capacity and a recognized global leader across pharmaceutical-grade cannabis production, clinical research, product innovation, and patient care. Through Tilray Medical, we have served hundreds of thousands of patients across more than 20 countries in some of the world’s most stringently regulated markets. This is how healthcare evolves. Tilray stands ready to partner with regulators and healthcare providers to responsibly expand access to medical cannabis and help shape the future of this industry in the United States.”
Research cannabis stocks at Investorideas.com
https://www.investorideas.com/Marijuana-Stocks/stocks_list.asp
Sign up for free trading and stock news alerts at Investorideas.com
This article is for informational purposes only and is not investment advice. See our full disclaimer.
